We have previously demonstrated that the ADP-ribosyltransferase-9 (ARTD9), also known as B-aggressive lymphoma protein (BAL1) and PARP9, acts as a novel oncogenic survival factor in high-risk, chemo-resistant, host response (HR) sub-types of diffuse large B-Cell lymphoma (HR-DLBCL) and as a crucial negative and positive co-regulator of IFNγ/STAT1-signaling[23]. The gene discussed is STAT1; the disease is diffuse large B-cell lymphoma.